This article has been updated to clarify comments made by Scientia Advisors' Patrick Terry.

BETHESDA, Md. — As far as XDx is concerned, it has jumped through all the right hoops to show the clinical utility of its AlloMap genomic heart transplant rejection test. But according to a company official, it hasn't seen the level of adoption it expected for the test because doctors don't have a monetary incentive to use it in place of cardiac biopsies.

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.

This webinar describes a study that used two independent next-generation sequencing (NGS) platforms to gain insight into the impact of different types of aneuploidies during preimplantation genetic testing.